Unknown

Dataset Information

0

Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications.


ABSTRACT:

Purpose

The complexity of sarcoma has led to the need for patient selection via in vivo biomarkers. Tumor endothelial marker-1 (TEM-1) is a cell surface marker expressed by the tumor microenvironment. Currently MORAb-004 (Ontuxizumab), an anti-TEM-1 humanized monoclonal antibody, is in sarcoma clinical trials. Development of positron emission tomography (PET) for in vivo TEM-1 expression may allow for stratification of patients, potentially enhancing clinical outcomes seen with Ontuxizumab.

Results

Characterization of cell lines revealed clear differences in TEM-1 expression. One high expressing (RD-ES) and one low expressing (LUPI) cell line were xenografted, and mice were injected with 89Zr-Ontuxizumab. PET imaging post-injection revealed that TEM-1 was highly expressed and readily detectable in vivo only in RD-ES. In vivo biodistribution studies confirmed high radiopharmaceutical uptake in tumor relative to normal organs.

Experimental design

Sarcoma cell lines were characterized for TEM-1 expression. Ontuxizumab was labeled with 89Zr and evaluated for immunoreactivity preservation. 89Zr-Ontuxizumab was injected into mice with high or null expressing TEM-1 xenografts. In vivo PET imaging experiments were performed.

Conclusion

89Zr-Ontuxizumab can be used in vivo to determine high versus low TEM-1 expression. Reliable PET imaging of TEM-1 in sarcoma patients may allow for identification of patients that will attain the greatest benefit from anti-TEM-1 therapy.

SUBMITTER: Lange SE 

PROVIDER: S-EPMC4914343 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications.

Lange Sara E S SE   Zheleznyak Alex A   Studer Matthew M   O'Shannessy Daniel J DJ   Lapi Suzanne E SE   Van Tine Brian A BA  

Oncotarget 20160301 11


<h4>Purpose</h4>The complexity of sarcoma has led to the need for patient selection via in vivo biomarkers. Tumor endothelial marker-1 (TEM-1) is a cell surface marker expressed by the tumor microenvironment. Currently MORAb-004 (Ontuxizumab), an anti-TEM-1 humanized monoclonal antibody, is in sarcoma clinical trials. Development of positron emission tomography (PET) for in vivo TEM-1 expression may allow for stratification of patients, potentially enhancing clinical outcomes seen with Ontuxizum  ...[more]

Similar Datasets

| S-EPMC4089496 | biostudies-literature
| S-EPMC5342488 | biostudies-literature
| S-EPMC5488699 | biostudies-literature
| S-EPMC6946129 | biostudies-literature
| S-EPMC4745807 | biostudies-other
| S-EPMC5486818 | biostudies-literature
| S-EPMC4116087 | biostudies-literature
| S-EPMC4410715 | biostudies-literature
| S-EPMC8446031 | biostudies-literature
| S-EPMC5680796 | biostudies-literature